Pharmafile Logo
Pharmafocus logo
Advanced Search

Brilinta

Showing 15 posts of 20 posts found.

shutter

AstraZeneca’s Brilinta combo reduces rate of disabling stroke or death in stroke patients, according to Phase 3 data

November 9, 2020
Research and Development, Sales and Marketing AstraZeneca, Brilinta, pharma

AstraZeneca has unveiled new Phase 3 data for Brilinta (ticagrelor) as a treatment for patients who have suffered an acute …

News
astrazeneca-sign

AstraZeneca presents strong Phase 3 Brilinta data for reducing CV risk

September 2, 2019
Research and Development, Sales and Marketing AstraZeneca, Brilinta, pharma

AstraZeneca has unveiled new positive Phase 3 data on the efficacy of Brilinta (ticagrelor) in combination with aspirin, showing that …

News
astrazeneca-sign

AstraZeneca’s Brilinta proves safety in heart attack patients at Phase 3

March 12, 2018
Research and Development, Sales and Marketing AstraZeneca, Brilinta, heart attack

AstraZeneca has revealed new Phase 3 data on its direct-acting P2Y12 receptor antagonist Brilinta (ticagrelor) at the American College of …

News
astrazeneca-sign

AstraZeneca’s Brilinta protects against adverse cardiovascular events for up to 5 years, new data reveals

September 7, 2017
Research and Development AstraZeneca, Brilinta, cardiovascular, heart attack, pharma, pharmaceutical, ticagrelor, trial

AstraZeneca has revealed new data supporting the long-term use and efficacy of its cardiovascular drug Brilinta (ticagrelor), showing that the …

News
astrazeneca_building_white

Extended use of AstraZeneca’s Brilinta reduces cardiovascular death risk

August 24, 2017
Research and Development AstraZeneca, Brilinta, cardiovascular, heart attack, life sciences, pharma, pharmaceutical

New data for AstraZeneca’s blood thinner Brilinta (ticagrelor) has shown that extended use of the drug can cut the risk …

News
brilinta

AstraZeneca’s Brilinta fails to best aspirin in treating stroke patients

March 23, 2016
Research and Development AstraZeneca, Brilinta, stroke

AstraZeneca has announced top-line results from the Phase III SOCRATES trial, confirming that twice-daily doses of its drug Brilinta (ticagrelor) failed …

News
astrazeneca image

AstraZeneca looks to oncology match-ups to boost sales

April 24, 2015
Sales and Marketing AstraZeneca, Brilinta, Celgene, Innate, Juno, farxiga, ticagrelor

AstraZeneca posted a 1% increase in revenue in its first-quarter 2015 financials – and is investing the money to back …

News
Brilinta image

Mixed results for AstraZeneca in high-profile Brilinta study

March 17, 2015
Sales and Marketing American College of Cardiology, AstraZeneca, Brilinta, EMA, FDA, ticagrelor

Experts say AstraZeneca is at risk of ‘diminishing returns’ in the clinical advantages of its blood-thinning drug Brilinta, after it …

News
AZ image

AstraZeneca looks for revenue boost via Actavis buy

February 6, 2015
Sales and Marketing Actavis, AstraZeneca, Brilinta, Forxiga, diabetes, fourth quarter, q4

AstraZeneca recorded a dip in revenue in the last quarter of 2014 and is looking to ramp up its respiratory …

News
Brilinta image

AstraZeneca’s troubled Brilinta gets welcome lift

January 14, 2015
Sales and Marketing AstraZeneca, Brilinta, FDA, US Department of Justice, acute coronary syndrome, ticagrelor

AstraZeneca has reported positive primary endpoint results for its anti-clogging drug Brilinta to treat patients who have had a heart …

News
Brilinta image

Mixed results for AZ’s troubled Brilinta

September 3, 2014
Sales and Marketing AstraZeneca, Brilinta, EMA, PCI, atlantic, heart, stent

The latest trial for AstraZeneca’s heart drug Brilinta (ticagrelor) has failed to meet expected results but suggests more flexible applications …

News
Brilinta image

Reprieve for AstraZeneca as US drops drug investigation

August 19, 2014
Sales and Marketing AstraZeneca, Brilinta, US, blood, justice, plato

The US Justice Department has pulled a controversial investigation into AstraZeneca’s pivotal clinical trial after finding no wrongdoing. The inquiry …

News
Astrazeneca image

Profits slump at AstraZeneca

April 24, 2014
Sales and Marketing AZD9291, AstraZeneca, BMS, Brilinta, Q1

AstraZeneca has continued its poor run of form, with operating profit in the first quarter of 2014 falling 40% on …

News
brilinta image

EMA questions Brilinta data

November 8, 2013
Sales and Marketing Brilinta, EMA, astrazenca, heart, ticagrelor

The European Medicines Agency is demanding more information from AstraZeneca on its troubled heart pill Brilinta. This rounds off a …

News
Astrazeneca image

AstraZeneca sees big sales drop in Q2

July 26, 2012
Sales and Marketing AstraZeneca, Brennan, Brilinta, Q2, Seroquel

AstraZeneca has today reported a large drop in revenue for the second quarter. The firm has been hit by major …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023